Home Carboxys (4R)-3-{[(2S)-5-oxopyrrolidin-2-yl]carbonyl}-1,3-thiazolidine-4-carboxylic acid

(4R)-3-{[(2S)-5-oxopyrrolidin-2-yl]carbonyl}-1,3-thiazolidine-4-carboxylic acid

CAS No.:
121808-62-6
Catalog Number:
AG00162L
Molecular Formula:
C9H12N2O4S
Molecular Weight:
244.2676
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
100mg
98%(HPLC)
In Stock USA
United States
$33
- +
1g
95%
In Stock USA
United States
$50
- +
5g
98%(HPLC)
In Stock USA
United States
$123
- +
10g
98%(HPLC)
In Stock USA
United States
$193
- +
25g
98%(HPLC)
In Stock USA
United States
$366
- +
Product Description
Catalog Number:
AG00162L
Chemical Name:
(4R)-3-{[(2S)-5-oxopyrrolidin-2-yl]carbonyl}-1,3-thiazolidine-4-carboxylic acid
CAS Number:
121808-62-6
Molecular Formula:
C9H12N2O4S
Molecular Weight:
244.2676
MDL Number:
MFCD00867583
IUPAC Name:
(4R)-3-[(2S)-5-oxopyrrolidine-2-carbonyl]-1,3-thiazolidine-4-carboxylic acid
InChI:
InChI=1S/C9H12N2O4S/c12-7-2-1-5(10-7)8(13)11-4-16-3-6(11)9(14)15/h5-6H,1-4H2,(H,10,12)(H,14,15)/t5-,6-/m0/s1
InChI Key:
UUTKICFRNVKFRG-WDSKDSINSA-N
SMILES:
O=C1CC[C@H](N1)C(=O)N1CSC[C@H]1C(=O)O
UNII:
785363R681
NSC Number:
759841
Properties
Complexity:
346  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
2  
Defined Bond Stereocenter Count:
0
Exact Mass:
244.052g/mol
Formal Charge:
0
Heavy Atom Count:
16  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
244.265g/mol
Monoisotopic Mass:
244.052g/mol
Rotatable Bond Count:
2  
Topological Polar Surface Area:
112A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-0.7  
Literature
Title Journal
Pidotimod: the state of art. Clinical and molecular allergy : CMA 20150101
Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression. Italian journal of pediatrics 20130101
Quantitative determination of pidotimod in human plasma by liquid chromatography tandem mass spectrometry: application to a bioequivalence study. Arzneimittel-Forschung 20120201
Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery. Journal of drug delivery 20120101
Molecular mechanism of macrophage activation by red ginseng acidic polysaccharide from Korean red ginseng. Mediators of inflammation 20120101
Water-in-oil-in-water double emulsions: an excellent delivery system for improving the oral bioavailability of pidotimod in rats. Journal of pharmaceutical sciences 20110601
Self-double-emulsifying drug delivery system (SDEDDS): a new way for oral delivery of drugs with high solubility and low permeability. International journal of pharmaceutics 20110516
Complementary treatment with oral pidotimod plus vitamin C after laser vaporization for female genital warts: a prospective study. Journal of medicine and life 20100815
Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of adefovir in human plasma and its application to a pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100801
Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level. International immunopharmacology 20091101
High-performance liquid chromatography-tandem mass spectrometry for the determination of pidotimod in human plasma and its application to a pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090815
Pidotimod: a reappraisal. International journal of immunopathology and pharmacology 20090101
Synergistic immunostimulatory effect of pidotimod and red ginseng acidic polysaccharide on humoral immunity of immunosuppressed mice. Die Pharmazie 20081201
Synergistic immunostimulating activity of pidotimod and red ginseng acidic polysaccharide against cyclophosphamide-induced immunosuppression. Archives of pharmacal research 20080901
Henoch-Schönlein purpura associated with pidotimod therapy. Clinical and experimental rheumatology 20080101
Microsphere-based protease assays and screening application for lethal factor and factor Xa. Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Urinary tract infection in children. Clinical evidence 20050601
[Comparative meta-analysis of immunoestimulant agents used in pediatric patients in Mexico]. Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 20050101
Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. The Journal of asthma : official journal of the Association for the Care of Asthma 20040101
Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Alternative medicine review : a journal of clinical therapeutic 20030801
[Therapy with cytokines and thymic factors in a complicated case of common variable immunodeficiency]. Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 20030101
Clinical evaluation and changes of the respiratory epithelium function after administration of Pidotimod in Greek children with recurrent respiratory tract infections. Minerva pediatrica 20020801
[Pidotimod in recurring respiratory infection in children with allergic rhinitis, asthma, or both conditions]. Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 20020101
Properties